Proteasome inhibitors in the treatment of B-cell malignancies.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Clinical Lymphoma

• Publication date

  2002-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3816/CLM.2002.N.011PMID 12141956
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• NF-κB in cancer: from innocent bystander to major culprit

  2002cited by this paper
• NF-kappaB in cancer: from innocent bystander to major culprit.

  2002cited by this paper
• Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

  2002cited by this paper
• 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer

  2001cited by this paper
• Protease inhibitors restore radiation‐induced apoptosis to Bcl‐2‐expressing lymphoma cells

  2001cited by this paper
• The role of nuclear factor-?b in the biology and treatment of multiple myeloma

  2001cited by this paper
• Analysis of expression of nuclear factor κB (NF‐κB) in multiple myeloma: downregulation of NF‐κB induces apoptosis

  2001cited by this paper
• Inhibition of 20S proteasome results in serum IL-6 and PSA decline in patients (pts) with androgen-independent prostate cancer (AIPCa) treated with the proteasome inhibitor PS-341

  2001cited by this paper
• The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.

  2001cited by this paper
• Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome.

  2001cited by this paper
• Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB

  2001cited by this paper
• Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells

  2001cited by this paper
• Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis.

  2001cited by this paper
• Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

  2001cited by this paper
• The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

  2001cited by this paper
• Characterization of NF-kappaB expression in Hodgkin's disease: inhibition of constitutively expressed NF-kappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells.

  2001cited by this paper
• Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

  2001cited by this paper
• Characterization of NF-κB Expression in Hodgkin’s Disease: Inhibition of Constitutively Expressed NF-κB Results in Spontaneous Caspase-Independent Apoptosis in Hodgkin and Reed-Sternberg Cells

  2001cited by this paper
• Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide.

  2000cited by this paper
• The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L).

  2000cited by this paper
• Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma.

  2000cited by this paper
• The Rel/NF-κB Family Directly Activates Expression of the Apoptosis Inhibitor Bcl-xL

  2000cited by this paper
• Proteasome inhibition measurements: clinical application.

  2000cited by this paper
• The proteasome controls the expression of a proliferation‐associated nuclear antigen Ki‐67

  2000cited by this paper
• Cancer statistics, 2000

  2000cited by this paper
• Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition

  2000cited by this paper
• Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells

  2000cited by this paper
• Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition.

  2000cited by this paper
• Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide

  2000cited by this paper
• New insights into role of microenvironment in multiple myeloma.

  2000cited by this paper
• Why Does Threonine, and Not Serine, Function as the Active Site Nucleophile in Proteasomes?*

  2000cited by this paper
• Proteasome inhibition: A novel mechanism to combat asthma.

  1999cited by this paper
• The SCFβ-TRCP–ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IκBα and β-catenin and stimulates IκBα ubiquitination in vitro

  1999cited by this paper
• NF- kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF- kappa B.

  1999cited by this paper
• The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro.

  1999cited by this paper
• Proteasome inhibitors: a novel class of potent and effective antitumor agents.

  1999cited by this paper
• The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis

  1999cited by this paper
• Increased sensitivity of CLL‐derived lymphocytes to apoptotic death activation by the proteasome‐specific inhibitor lactacystin

  1999cited by this paper
• Signal-induced ubiquitination of IκBα by the F-box protein Slimb/β-TrCP

  1999cited by this paper
• Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.

  1999cited by this paper
• Signal-induced ubiquitination of IkappaBalpha by the F-box protein Slimb/beta-TrCP.

  1999cited by this paper
• The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis.

  1999cited by this paper
• Phosphorylation and proteasome-dependent degradation of Bcl-2 in mitotic-arrested cells after microtubule damage.

  1999cited by this paper
• NF-κB Induces Expression of the Bcl-2 Homologue A1/Bfl-1 To Preferentially Suppress Chemotherapy-Induced Apoptosis

  1999cited by this paper
• Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts

  1998cited by this paper
• Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor.

  1998cited by this paper
• Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids.

  1998cited by this paper
• The proteasome is involved in angiogenesis.

  1998cited by this paper
• Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells.

  1998cited by this paper
• NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.

  1998cited by this paper
• Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1.

  1998cited by this paper
• The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis.

  1998cited by this paper
• Activation of the cell death program by inhibition of proteasome function.

  1997cited by this paper
• Structure of 20S proteasome from yeast at 2.4Å resolution

  1997cited by this paper
• Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of I kappa B-alpha.

  1996cited by this paper
• How Proteolysis Drives the Cell Cycle

  1996cited by this paper
• p53-dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts.

  1996cited by this paper
• Role of IB Ubiquitination in Signal-induced Activation of NF-B in Vivo(*)

  1996cited by this paper
• Role of IkappaBalpha ubiquitination in signal-induced activation of NFkappaB in vivo.

  1996cited by this paper
• Critical Role for Lysines 21 and 22 in Signal-induced, Ubiquitin-mediated Proteolysis of IB- (*)

  1996cited by this paper
• Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution.

  1995cited by this paper
• Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway.

  1995cited by this paper
• Catalytic mechanism of the 20S proteasome of Thermoplasma acidophilum revealed by X-ray crystallography.

  1995cited by this paper
• Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway.

  1995cited by this paper
• Activation of NF-kappa B requires proteolysis of the inhibitor I kappa B-alpha: signal-induced phosphorylation of I kappa B-alpha alone does not release active NF-kappa B.

  1995cited by this paper
• Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination.

  1995cited by this paper
• Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27.

  1995cited by this paper
• The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression.

  1995cited by this paper
• p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest.

  1994cited by this paper
• Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha.

  1993cited by this paper
• Cancer : Principles and Practice of Oncology

  1982cited by this paper

• O-mannosylation and protein maturation check-points represent therapeutic opportunities in BRAF fusion protein oncogenesis

  2025cites this paper
• Excessive activation?induced cytidine deaminase accumulated by proteasome inhibitors rescues abnormal class switch in activated B?cell?like diffuse large B?cell lymphoma.

  2025cites this paper
• Understanding the Biological Basis of Polygenic Risk Scores and Disparities in Prostate Cancer: A Comprehensive Genomic Analysis

  2024cites this paper
• The Impact of Induction Regimes on Immune Responses in Patients with Multiple Myeloma

  2021cites this paper
• Lactacystin: first-in-class proteasome inhibitor still excelling and an exemplar for future antibiotic research

  2019cites this paper
• Plasma cell and B cell-targeted treatments for use in advanced multiple sclerosis.

  2019cites this paper
• A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response

  2019cites this paper
• Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma

  2017cites this paper
• Proteasome inhibitors in cancer therapy: Treatment regimen and peripheral neuropathy as a side effect

  2017cites this paper
• Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review

  2015cites this paper
• Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo

  2013cites this paper
• Free radicals and antioxidants: how to reestablish redox homeostasis in chronic diseases?

  2013cites this paper
• Mechanistic Rationale and Clinical Evidence for the Efficacy of Proteasome Inhibitors against Indolent and Mantle Cell Lymphomas

  2012cites this paper
• Proteasome and cancer.

  2012cites this paper
• Protein Oxidation in Some Age‐Related Diseases

  2012cites this paper
• Spindle poisons and cell fate: a tale of two pathways.

  2011cites this paper
• DNA Repair, Cancer and Cancer Therapy

  2011cites this paper
• Erratum zu Charakterisierung der molekularen Mechanismen des Adipokins Adiponectin bei der Nicht-alkoholischen Steatohepatitis (NASH)

  2011cites this paper
• Spindle Poisons and Cell Fate : A Tale of Two Pathways

  2011cites this paper
• Future Cancer Therapy with Molecularly Targeted Therapeutics: Challenges and Strategies

  2011cites this paper
• Intracellular Rescue of the Uroporphyrinogen III Synthase Activity in Enzymes Carrying the Hotspot Mutation C73R*

  2011cites this paper
• Ubiquitin-mediated protein degradation and methylation-induced gene silencing cooperate in the inactivation of the INK4/ARF locus in Burkitt lymphoma cell lines

  2011cites this paper
• Regulation of Hdm2/HdmX-mediated ubiquitination and neddylation

  2010cites this paper
• The Expanding Role of Proteasome-Based Therapy in the Treatment of Hematologic Malignancies

  2010cites this paper
• Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia (TACL) consortium

  2010cites this paper
• Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma

  2010cites this paper
• The Treatment of Traumatic Brain Injury with Velcade

  2010cites this paper
• Role of the ubiquitin-proteasome pathway in downregulation of the gap-junction protein Connexin43 by TNF-{alpha} in human corneal fibroblasts.

  2010cites this paper
• The proteasomal system.

  2009cites this paper
• Clinical variability and expression of the NBN c.657del5 allele in Nijmegen Breakage Syndrome.

  2009cites this paper
• Comparative proteomic analysis to discover potential therapeutic targets in human multiple myeloma

  2009cites this paper
• An Insilico Approach To Identify Better 20s Type Proteosomal Inhibitor Through Analysis Of Binding Affinity

  2009cites this paper
• Therapeutic Options in Multiple Myeloma: Focus on Bortezomib

  2009cites this paper
• Up-stream events in the nuclear factor κB activation cascade in response to sparsely ionizing radiation

  2009cites this paper
• BLyS/BR3 Receptor Signaling in the Biology and Pathophysiology of Aggressive B-Cell Lymphomas

  2009cites this paper
• Abrogation of U266 Multiple Myeloma Cell Proliferation Via Inhibition of NF-κB Activation by Curcumin

  2008cites this paper
• Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia

  2008cites this paper
• Treatment of Relapsed/Refractory Hodgkin Lymphoma

  2007cites this paper
• Current Therapies for Multiple Myeloma

  2007cites this paper
• Target validation in drug discovery.

  2007cites this paper
• CANCER DRUG DISCOVERY AND DEVELOPMENT

  2007cites this paper
• IKK-2/NF-κB-DEPENDENT TRANSCRIPTION

  2007cites this paper
• Possible tetramerisation of the proteasome maturation factor POMP/proteassemblin/hUmp1 and its subcellular localisation.

  2006cites this paper
• Proteasome inhibition with bortezomib: A new therapeutic strategy for non‐Hodgkin's lymphoma

  2006cites this paper
• Functional analysis of the cytoplasmic domain of complement receptor type II (CR2/CD21)

  2006cites this paper
• Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells.

  2006cites this paper
• 3 Re-induction Therapy with Ifosfamide / Vinorelbine ( IV )

  2006cites this paper
• Proteasome inhibition as novel treatment strategy in leukaemia

  2006cites this paper
• A phase II study of bortezomib in the treatment of metastatic malignant melanoma

  2005cites this paper
• Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment.

  2005cites this paper
• ER stress and the unfolded protein response.

  2005cites this paper
• Oncogenes as molecular targets in lymphoma.

  2005cites this paper
• Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2

  2005cites this paper
• Tumor Lysis Syndrome After Bortezomib Therapy for Plasma Cell Leukemia

  2005cites this paper
• Severe Acute Enteritis in a Multiple Myeloma Patient Receiving Bortezomib and Spinal Radiotherapy: Case Report

  2005cites this paper
• Proteasome inhibition in multiple myeloma: therapeutic implication.

  2005cites this paper
• Proteasome inhibitor therapy in multiple myeloma

  2005cites this paper
• Probing structure in the polymorphic domain of the L-enantiomer of N-benzoyl-phenylalanine by means of 2D solid-state NMR spectroscopy and DFT calculations.

  2005cites this paper
• Microarray studies of prognostic stratification and transformation of follicular lymphomas.

  2005cites this paper
• The proteasome: a suitable antineoplastic target

  2004cites this paper
• Update on the proteasome inhibitor bortezomib in hematologic malignancies.

  2004cites this paper
• Nuclear factor-kappa B regulates cyclooxygenase-2 expression and cell proliferation in human colorectal carcinoma tissue.

  2004cites this paper
• Inhibitor of apoptosis proteins: new therapeutic targets in hematological cancer?

  2004cites this paper
• Recent advances in the medicinal chemistry of alpha-aminoboronic acids, amine-carboxyboranes and their derivatives.

  2004cites this paper
• The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib.

  2004cites this paper
• Clinical Molecular Diagnostics for Proteasome Inhibitors in Cancer Therapy

  2004cites this paper
• Proteasome Inhibitors in Cancer Therapy

  2004cites this paper
• Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human colorectal carcinoma tissue.

  2004cites this paper
• The Proteasome in Cancer Biology and Therapy

  2004cites this paper
• Targeted therapy for cancer

  2004cites this paper
• Chemotherapeutic agents that induce mitochondrial apoptosis.

  2004cites this paper
• Targeting I kappa B kinase for the treatment of inflammatory and other disorders.

  2003cites this paper
• Proteasomes as drug targets.

  2003cites this paper
• [Perspectives on the oncologist pharmacopoeia].

  2003cites this paper
• Intracellular localization of proteasomes.

  2003cites this paper
• Mieloma múltiple. Tratamiento

  2003cites this paper
• The mammalian unfolded protein response.

  2003cites this paper
• Myélome multiple. Traitement

  2003cites this paper
• Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.

  2003cites this paper
• Clinical update: proteasome inhibitors in hematologic malignancies.

  2003cites this paper
• Phase II Trials of Bortezomib (PS-341, Velcade™), a Selective Proteasome Inhibitor, in Non-Hodgkin's Lymphoma

  2003cites this paper